Skip to main content
. 2021 May 31;13:17588359211015493. doi: 10.1177/17588359211015493

Figure 1.

Figure 1.

Tomography scan assessments of the right parotid lesion at different time points. (a) Before starting the first course of carboplatin/cetuximab. (b) After completing five cycles of carboplatin/cetuximab and before starting the first course of pembrolizumab. (c) After completing four cycles of pembrolizumab and before starting the first course of pembrolizumab/cetuximab. (c) Three months and (d) 2 years after introduction of pembrolizumab/cetuximab.